FAST NEWS: Lepu Biopharma to raise $32 million in share sale
The Latest: Innovative drug maker Lepu Biopharma Co. Ltd. (2157.HK) announced on Friday it will place up to 51.17 million shares, or about 2.99% of its overall issued share capital, for…
Lepu Biopharma gets taste of spring with first revenues
The ADC-focused drug company logged its first-ever sales late last year, kicking of the next phase of its development Key Takeaways: Lepu Biopharma began to sell its first product last…
Laekna IPO hopes to hitch a ride on Novartis ties
The producer of drugs licensed from third parties is banking on ties to the Swiss drug maker, as one of its key products nears the regulatory finish line Key Takeaways:…
Lepu Biopharma Marches Towards First Sales as Costs Mount
Company’s Puyouheng cancer immunotherapy drug was approved for two indications in China, becoming its first commercialized product Key Takeaways: Lepu Biopharma will incur more operational costs as it builds up…
Lepu ScienTech Revives IPO After Policy Move Brightens Its Prospects
China’s leading supplier of congenital heart disease devices made its third filing earlier this month for a Hong Kong IPO Key Takeaways: After taking its Lepu Biopharma unit public in…
3D Medicines Bleeds Red Ink As It Struggles to Swim in ‘Red Ocean’
The loss-making innovative oncology drug company with just one approved product on the market is making a third tilt for a listing on the Hong Kong Stock Exchange Key Takeaways:…
With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors
The biotechnology company, which is facing ballooning losses without any revenue like many of its peers, has filed for an IPO in Hong Kong (more…)
Recent Articles
RELATED ARTICLES
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
HBM gets health boost from drug licensing deals
2142.HK
- Funding boost gets Sunho Biologics over the IPO filing line
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
